C12N 2710/10023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2710/10023 (Virus like particles [vlp]) appears on 8 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 18
- Assignees
- 14
- Inventors
- 37
- Latest grant
- 8 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 2 |
| 2019 | 2 | 2 |
| 2020 | 0 | 3 |
| 2021 | 1 | 0 |
| 2022 | 2 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 3 |
| 2025 | 2 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy8 Jul 2025US 12,350,375 B2Leukocare AG
- Variant RNAi17 Jun 2025US 12,331,296 B2Genzyme Corporation
- Variant RNAi14 Mar 2023US 11,603,529 B2Genzyme Corporation
- Methods and compositions for combination immunotherapy7 Jun 2022US 11,352,642 B2Etubics Corporation
- Method for detecting protein-protein interactions in a cell utilizing particle-forming polypeptide-bait fusion proteins and virus-like particles1 Feb 2022US 11,237,174 B2Universiteit Gent
- Tet-r expression cassettes and cell lines16 Jul 2026US 2026/0201417 A1Cevec Pharmaceuticals GmbH
- Variant rnai18 Sep 2025US 2025/0290075 A1Genzyme Corporation
- Temperature-responsive virus storage system11 Apr 2024US 2024/0117379 A1Trizell Ltd.
- Temperature-responsive virus storage system8 Feb 2024US 2024/0043873 A1Trizell Ltd.
- Gorilla adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof4 Jan 2024US 2024/0002879 A1
Most cited
By later US patents
- Dengue vaccines1US 10,350,285 B2Oxford University Innovation Limited · 2019
- Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins1US 10,444,245 B2Universiteit Gent · 2019
- Methods and compositions for combination immunotherapy1US 11,352,642 B2Etubics Corporation · 2022
- Variant RNAi1US 11,603,529 B2Genzyme Corporation · 2023